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Abstract: 5-Fluorouracil has been a mainstay in the treatment of colorectal cancer for nearly 
five decades; however, the use of oral formulations of the medication has been gaining   increasing 
traction since capecitabine was approved for use in adjuvant settings by the US Food and Drug 
Administration in 2005. The use of capecitabine has since spread to a number of off-label indica-
tions, including the treatment of advanced or metastatic colorectal cancer and the neoadjuvant 
treatment of rectal cancer. In light of increasing utilization, it is critical that clinicians have a 
firm understanding of the literature supporting capecitabine across various settings as well as 
the attributes of the drug, such as its dosing recommendations, side-effect profile, and use in 
the elderly. The purpose of this review is to synthesize the literature in a fashion that can be 
used to help guide decisions. In a setting of increasing focus on cost, the pharmacoeconomic 
literature is also briefly reviewed.
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Introduction
5-Fluorouracil (5-FU) was initially introduced over 40 years ago and has remained a 
mainstay in treatment regimens for colorectal cancer (CRC) since that time, both alone 
and in combination with other agents. Its impact on cancer care has been substantial as 
CRC is the third most commonly diagnosed cancer in the United States with 142,570 
new cases in 2009, and it is the third leading cause of cancer death in both men and 
women with a combined 51,370 fatalities in the same year.1 Despite the importance 
of 5-FU to cancer care, its short half-life, requirement for a central line, and the need 
for continuous infusions led researchers to design an oral formulation of the drug. 
In June 2005, capecitabine (Xeloda®; Hoffman-LaRoche, Nutley, NJ) was approved 
by the Food and Drug Administration (FDA) as an oral prodrug of 5-FU for use as 
monotherapy in the adjuvant setting when treating Dukes’ stage C CRC.
Capecitabine has a number of advantages over traditional 5-FU. After absorption 
across the digestive tract, it is converted to 5-FU through three sequential enzymatic 
reactions. The final enzyme in the pathway, thymidine phosphorylase (TP), is believed 
to be present at disproportionately high levels in tumor tissue, which is said to increase 
both the efficacy and tolerability of the agent through targeted delivery.2 Its oral admin-
istration simplifies care, frequently precluding the need for central venous access or 
infusion pumps. As a result, capecitabine is increasingly used for off-label indications 
in CRC, including monotherapy in the advanced or metastatic setting, combination 
therapy in conjunction with oxaliplatin in the advanced or metastatic setting, and with 
concurrent radiation for the neoadjuvant treatment of rectal cancer.3,4 As off-label use Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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of capecitabine increases, it becomes even more important 
to understand the efficacy and tolerability across settings, 
which support its utilization in order to ensure the   appropriate 
treatment of patients.
The purpose of this review is, therefore, to provide an 
overview of capecitabine’s mechanism of action and rate 
of adverse events as well as an analysis of the evidence 
  supporting its use in the settings outlined above. In addition, 
this article will highlight the regional differences in tolerance 
that affect dosing decisions and the evidence behind its use 
in the elderly, which remains an area of controversy. Finally, 
the economic literature will be discussed. The decision to 
prescribe capecitabine is a complex one; however, increasing 
evidence is emerging to guide clinicians.
Methods
For this review, English-language literature was identified 
through a search of PubMed (from 1966 to October 2010) 
and a search of The Proceedings of the American Society 
of Clinical Oncology (ASCO) (from January 1995 to July 
2010). Search terms included capecitabine, Xeloda, colorec-
tal cancer, colon cancer, and rectal cancer. The references 
of identified articles were reviewed for additional articles 
of interest. Studies identified as important to the field were 
included in the review.
Mode of action and pharmacokinetics
5-FU is an antimetabolite which disrupts DNA and RNA 
synthesis and repair, leading to cell death. Using folate as 
a cofactor, the drug is converted to active nucleotides, such 
as fluorodeoxyuridine monophosphate, which inhibit the 
enzyme thymidylate synthase.2,5 This in turn results in the 
formation of unbalanced pools of deoxynucleotide triphos-
phates that are used in DNA synthesis, leading to DNA strand 
breaks. Another metabolite of the drug, fluorouridine triphos-
phate, acts as a false nucleotide in RNA formation, inhibiting 
protein synthesis.6 With time, these complications result in 
cell death intended to arrest the progression of disease.
5-FU cannot be given orally due to significant variation 
in its bioavailability, leading to the design of a prodrug to 
overcome this drawback. The result is an oral fluoropyrimi-
dine carbamate that mimics the serum concentrations of a 
continuous 5-FU infusion. Capecitabine (N-(1-(5-deoxy-β-
d-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyridinyl)-n-
pentyl carbamate) is a crystalline substance, absorbed via the 
gastrointestinal tract and converted to 5-FU in three sequen-
tial enzymatic reactions. Although the first two steps occur in 
the liver, the final conversion from 5′-deoxy-5-fluorouridine 
to 5-FU is believed to preferentially take place in tumor 
tissue because TP is expressed in higher concentrations in 
  neoplastic tissue.7 In a study to test this hypothesis, 5-FU 
was found to be present at three times higher concentration 
in tumor tissue when compared to adjacent, normal tissue and 
at 21 times the concentration found in the plasma.8 In addi-
tion, a number of studies have shown that TP is upregulated 
in tumor tissue after treatment with radiotherapy or cytotoxic 
agents besides 5-FU, providing a possible explanation for the 
synergistic effect seen with combination therapy.9–12
Multiple studies have also assessed the pharmacokinetics 
of capecitabine. The drug is nearly 100% bioavailable, and a 
linear increase is seen in both maximum plasma concentration 
(Cmax) and area under the curve (AUC) with dose titration.13 
There is no evidence of drug accumulation across a range 
of doses, and pharmacokinetics were found to be similar 
between Caucasian and Japanese patient populations.14,15 
The half-life of capecitabine is between 0.49 and 0.89 hours, 
while the half-life of the metabolite (5-FU) extends from 
0.67 to 1.15 hours.13,14,16 Of additional interest, capecitabine 
is supposed to be dosed within 30 minutes of food. A study 
conducted prior to capecitabine’s approval compared drug 
levels after an overnight fast to its administration within 
30 minutes of food. Researchers found a 60% decrease in 
the Cmax and a 31% decrease in the AUC when given with 
food, but the change in AUC of the cytotoxic end product, 
5-FU, exhibited less variation.17 The importance of taking 
the medication with food is, therefore, unclear, but it is still 
recommended to be taken within 30 minutes of a meal, as 
this was the setting in which it was tested.
Dosing
The ideal dosing of capecitabine is controversial as regional 
differences have been seen in the tolerance of oral fluoro-
pyrimidines. In 2008, Haller et al published a retrospective 
analysis of patients with CRC who were treated with capecit-
abine at sites around the world.18 Among 1189 patients with 
metastatic disease, the authors found that those enrolled in 
trials in the United States had higher rates of grade 3 and 4 
adverse events (relative risk [RR], 1.77), an increase in the 
frequency of dose reduction (RR, 1.72), and higher rates of 
treatment discontinuation (RR, 1.83). The results among 
1864 patients receiving treatment in the adjuvant setting also 
showed increased grade 3 and 4 adverse events (RR, 1.47) 
and higher rates of discontinuation (RR, 2.09). On further 
analysis, East Asian patients fared the best overall.
This was again demonstrated in the TREE trials.19 
In the first of two (TREE-1), 150 patients were treated with Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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a combination of capecitabine and oxaliplatin (XELOX) at 
a capecitabine dose of 1000 mg/m2. In the subsequent trial 
(TREE-2), the capecitabine dose was reduced to 850 mg/m2 for 
the 223 enrolled patients. The dose reduction was made after 
the data monitoring committee reviewed the safety data of the 
initial study. In TREE-2, an increase in hypertension was seen 
due to the addition of bevacizumab, while the overall rate of 
grade 3 and 4 toxicities improved as shown in Table 1.
A number of possible explanations for the variation in 
side effect profiles between countries have been proposed. 
Folic acid supplementation is much more widespread in 
the United States than in Europe which might account for 
a portion of the differences. Pharmacogenetics may also 
play a role as genetic differences between Caucasian and 
Japanese patients have been discovered, but this is unlikely 
to explain the variation in events between the United States 
and European populations who have similar genetic profiles.20 
Variability in trial reporting, psychosocial factors, and differ-
ences in body weight have also been considered as causative 
factors in the regional toxicity variation, but none have been 
substantiated.
Capecitabine was initially approved at a dose of 
2500 mg/m2 for 14 of every 21 days; however, this dose results 
in increased toxicity in the United States as outlined above. 
The most recent National Comprehensive Cancer Network 
guidelines recommend starting doses of 850 or 1000 mg/m2 
twice daily when used with oxaliplatin for advanced or 
metastatic colorectal cancer (mCRC), while the group recom-
mends using 1000–1250 mg/m2 twice daily when it is given 
as monotherapy.3 With concurrent radiation for rectal cancer, 
the recommended dose is 850 mg/m2 twice daily.4
Treatment strategies
Capecitabine is used to treat CRC in three settings: for 
adjuvant treatment, as monotherapy or in combination with 
other agents for advanced or metastatic disease, and with 
concurrent radiation for the neoadjuvant treatment of rectal 
cancer. The most robust body of literature addresses its role 
in metastatic disease, but the literature across all indications 
is increasing.
Adjuvant treatment of CRC
Capecitabine was initially approved by the FDA in 2005 
for treatment of Dukes’ C (now commonly referred to as 
stage III) CRC in the adjuvant setting. This approval was 
based largely on results from the Xeloda in Adjuvant Colon 
Cancer Therapy (X-ACT) trial in which 1987 patients with 
previously resected stage III colon cancer were randomized 
to either capecitabine at 1250 mg/m2 (1004 patients) twice 
daily or bolus 5-FU plus leucovorin via the Mayo regimen 
(983 patients).21 At a median of 3.8 years of follow-up, the 
authors concluded that capecitabine demonstrated noninfe-
riority to 5-FU. Although relapse-free survival was signifi-
cantly improved (hazard ratio [HR], 0.86; 95% confidence 
interval [CI]: 0.74–0.99), differences in disease-free survival 
(DFS) (HR, 0.87; 95% CI: 0.75–1.00) and overall survival 
(OS) (HR, 0.84; 95% CI: 0.69–1.01) bordered on statistical 
significance. Of interest, 83% of patients receiving capecit-
abine completed their treatment course, but 57% required 
dose modifications. Overall, the toxicity profile of capecit-
abine was superior with the exception of a greater frequency 
of hand–foot syndrome (HFS). As a result, capecitabine is 
generally considered to be noninferior to 5-FU in the adjuvant 
setting, supporting its use among those patients who chose 
to undergo treatment.
A number of ongoing studies are investigating capecit-
abine in a variety of adjuvant settings. Preliminary results 
from N016968 demonstrated significant increases in 3-, 
4-, and 5-year DFS rates for stage III patients receiving 
XELOX when compared to 5-FU and leucovorin.22 A large 
European study of the adjuvant treatment of CRC (AVANT) 
is comparing XELOX plus bevacizumab to either FOLFOX 
alone or FOLFOX with bevacizumab. It is yet to release 
final results, but initial indications suggest no differences in 
outcomes between the different regimens.23 The European 
PETACC-6 study is comparing neoadjuvant capecitabine 
and radiation, followed by surgery and adjuvant capecitabine 
to the same regimen plus oxaliplatin in patients with rectal 
cancer.24 A phase III study enrolling in the United Kingdom 
is examining the benefit of adjuvant XELOX in locally 
advanced rectal cancer.25 These studies suggest a growing 
interest in capecitabine in a variety of regimens in the adju-
vant setting. However, since no definitive data are presently 
Table 1 incidence of grade 3 and 4 adverse events (%) in mCRC 
treatments19
Parameter TREE-1 (n = 150) TREE-2 (n = 223)
Nausea/vomiting 38 21
Diarrhea 31 19
Dehydration 27 8
Paresthesia 21 11
Hand–foot syndrome 19 10
Fatigue 6 11
Anemia 6 0
Leukopenia 2 0
Hypertension 2 15
Adapted from Hochster et al19, with permission © 2008 American Society of Clinical 
Oncology. 
Abbreviation: mCRC, metastatic colorectal cancer.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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available, FOLFOX remains the regimen of choice over 
XELOX when combination treatment is being considered 
in the adjuvant setting. For patients who are resistant to car-
rying a pump, the consideration of capecitabine or XELOX 
is within reason.
Concurrent chemotherapy and radiation 
in rectal cancer
Preoperative chemotherapy and radiation have become the 
standard of care with T3 and T4 rectal cancer as it results in 
lower rates of local recurrence when compared to   adjuvant 
chemotherapy and radiation. The regimen used by the   German 
Rectal Cancer Study Group, which first demonstrated the role 
of neoadjuvant treatment, consists of two doses of infusional 
5-FU on weeks 1 and 5.26 This has been routinely used since 
that time; however, capecitabine has recently been gaining 
traction as an off-label alternative to 5-FU. Although preclini-
cal studies showed promise that capecitabine could be more 
effective than 5-FU due to the upregulation of TP,24 the quality 
of evidence supporting this practice is not robust.
A number of trials have been performed looking at mono-
therapy with capecitabine, and a summary of the phase II 
trials is shown in Table 2. A range of downstaging following 
treatment has been found to be between 51% and 76% in these 
studies, with a complete response seen on pathology between 
12% and 31% of the time.27–30 The largest of these studies 
was a trial of 95 patients in South Korea with T3, T4, or N1 
disease. They were treated with capecitabine at 825 mg/m2 
twice daily while receiving 50 Gy of radiation followed by a 
total mesorectal excision.30 This trial was not randomized or 
blinded and patients were compared to historical controls. Out 
of 95 patients enrolled, 97% were able to undergo complete 
resection, 76% of the tumors were downstaged at the time 
of surgery, and 12% had a complete response on pathologic 
evaluation. These results were said to be consistent with his-
torical results seen with 5-FU; however, the trial results did 
not include outcome data such as progression-free   survival 
(PFS) or OS.
Another important study which has only been presented 
in abstract form, is a Phase III trial from Germany which 
randomized patients receiving 50.4 Gy of radiation to 
concurrent infusional 5-FU or capecitabine at 825 mg/m2 
twice daily.31 The initial results have been presented on 121 
patients. Those treated with capecitabine had higher rates of 
tumor downstaging (52% vs 39%; P = 0.16) and increased 
N0 status (71% vs 56%; P = 0.09); however, neither result 
was statistically significant. As expected, the patients receiv-
ing capecitabine had less   leukopenia (25% vs 35%; P = 0.04) 
but more HFS (31% vs 2%; P , 0.001). The toxicity profiles 
were otherwise similar.
A number of trials have also looked at the addition of 
oxaliplatin, irinotecan, or targeted agents to chemoradiation 
with capecitabine. The results from phase II and III trials on 
the subject are also outlined in Table 2. The possible utility 
of oxaliplatin was extrapolated from the colon cancer setting 
where a radiosensitizing effect and DFS benefit have been 
shown. Among phase II studies, downstaging ranged from 
53% to 67% with complete responses seen at pathologic 
evaluation 14% to 20% of the time.32–36 However, a phase III 
study showed only a nonsignificant gain in complete response 
despite a significant increase in toxicity. In a trial by Chua 
et al, they amended the protocol to exclude patients with 
cardiac disease after deaths in 8 of an initial 77 patients 
receiving the regimen.33 This causes concern for an otherwise 
promising regimen.
Irinotecan has less evidence supporting its use, in part 
because of overlapping toxicities. Although two small 
phase I/II studies have been performed which show com-
plete response rates of 15%, the rate of grade 3 or 4 diarrhea 
was 20% in one of the studies and the rate of grade 3 or 4 
leukopenia was 25% in the other.37,38 As such, this cannot be 
considered a viable alternative at present. Although studies 
have also looked at targeted therapies, including cetuximab 
and bevacizumab, the results are not yet robust enough to 
make clinical decisions. Trials including phase II arms are 
again outlined in Table 2.39,40
Trials assessing the treatment of rectal cancer with 
concurrent capecitabine and radiation are promising, but 
the comparability between 5-FU and capecitabine in this 
setting has not been definitively proven. An ongoing trial, 
NSABP R-04, will shed more light on the topic as patients 
are enrolled in a two-by-two factorial design in order to 
compare capecitabine to infusional 5-FU, with or without 
oxaliplatin. The final publication of this study as well as the 
German trial mentioned above should help shed light on the 
topic. Based on the currently available evidence, capecitabine 
can be reasonably considered in patients who are reluctant 
to receive continuous infusion therapy during the course of 
radiation.
Advanced and mCRC
The use of capecitabine in the advanced or metastatic settings 
is of interest, as quality of life is particularly important in 
patients who are often unlikely to be cured of their disease. 
In a recent analysis of patient preference, it was found that 
95% preferred oral palliative chemotherapy prior to starting Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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treatment, and 64% retained this preference after treatment.41 
This is consistent with prior research on the matter; however, 
70% of patients have stated that they are not willing to do so if 
it meant a lower response rate.42 A meta-analysis published in 
October 2010 found 22 trials comparing capecitabine-based 
regimens to treatment with 5-FU in the metastatic setting.43 
A total of 12 studies was excluded from the analysis, most 
often due to a lack of randomization, and the results included 
both monotherapy and combination regimens. Although the 
analysis found a significant improvement in PFS favoring 
capecitabine, the gain in OS was not significant (RR, 0.89; 
95% CI: 0.73–1.09).
It is important to look at the specific combinations to help 
inform decisions. To evaluate capecitabine as monotherapy 
in advanced disease, two phase III trials were conducted at 
a dose of 1250 mg/m2 twice daily for 2 of every 3 weeks. 
In both trials, capecitabine was compared to the Mayo 
Clinic regimen of bolus 5-FU and leucovorin, which differs 
from the continuous infusion protocol used in most modern 
regimens.44,45 The studies showed improved response rates 
favoring capecitabine (18.9% vs 15.0% and 24.8% vs 15.5%); 
however, these results were not statistically significant, and 
both time to progression and OS were not significantly differ-
ent. Patients treated with capecitabine exhibited lower rates 
of neutropenia, stomatitis, and alopecia but had higher rates 
of cutaneous HFS and uncomplicated hyperbilirubinemia.
These studies have been supplemented with numerous 
others looking at the role of capecitabine as a replacement for 
5-FU and leucovorin in either the FOLFOX (5-FU, leucovorin, 
and oxaliplatin) or FOLFIRI (5-FU, leucovorin, and irinotecan) 
regimens. Of note, after substituting capecitabine in place of 
5-FU, the combinations are instead referred to as XELOX and 
CAPOX or XELIRI and CapeIRI. The dosing of the different 
agents in the regimens is outlined in the footnote to Table 3.
Numerous phase III trials have looked at the differences 
between FOLFOX and XELOX in first- and second-line set-
tings, some of which have been published only in abstract 
form.46–50 These trials are again outlined in Table 3. All of 
the trials demonstrated XELOX to have similar outcomes to 
FOLFOX, including rates of response, PFS, and OS. None 
found XELOX to be superior, and most have actually shown 
that the survival results for XELOX lag those of FOLFOX 
without being statistically significant.
Trial NO16966 was the most robust assessment of the 
topic.46 It was Roche-sponsored and compared XELOX to 
FOLFOX4 for first-line therapy in the advanced or   metastatic 
setting. It initially included 634 patients; however, an 
  additional 1400 patients were added after the protocol was 
altered to allow two-by-two randomization with the addition 
of bevacizumab. Among the 2034 patients enrolled, there was 
no significant difference in primary outcomes seen between 
the XELOX and FOLFOX4 arms, as PFS was found to be 8.0 
and 8.5 months (HR, 1.04; 95% CI: 0.93–1.16), respectively, 
while OS were 19.8 and 19.6 months (HR, 0.99; 95% CI: 
0.88–1.12). The authors concluded that XELOX is noninfe-
rior for the up-front treatment of metastatic disease.
Multiple studies have also reported on the combina-
tion of capecitabine and irinotecan, as outlined in Table 3. 
The CAIRO study investigated the benefit of sequential 
versus combination therapy using capecitabine, oxaliplatin, 
and irinotecan.51 Patients receiving CapeIRI in this trial 
reportedly experienced gastrointestinal toxicity within an 
acceptable range.   However, two subsequent studies reported 
contrasting findings. The phase III BICC-C trial compared 
FOLFIRI, CapeIRI, and irinotecan with bolus 5-FU (mIFL).52 
Capecitabine was dosed at 1000 mg/m2 twice daily. In this 
study, FOLFIRI was found to be superior to either alternative 
with a median PFS of 7.6 months compared to 5.9 months for 
mIFL (P = 0.004) and 5.8 months for CapeIRI (P = 0.015). 
OS results trended toward superiority at 23.1 months for 
FOLFIRI, 17.6 months for mIFL (P = 0.09), and 18.9 months 
for CapeIRI (P = 0.27); however, none of the results achieved 
significance. CapeIRI also had higher rates of grade 3 and 
4 diarrhea (48%), dehydration (19%), nausea (18%), and 
vomiting (16%). The authors considered the possibility that 
worse PFS with CapeIRI was attributable to treatment dis-
continuation from toxicity. The data were reanalyzed after 
excluding those patients who discontinued treatment within 
30 days due to toxicity, and PFS for CapeIRI was still inferior 
to that of FOLFIRI.
A third trial was designed to show noninferiority of 
CapeIRI to FOLFIRI in the first-line metastatic setting 
(EORTC 40015).53 In this two-by-two study, patients were 
randomized to receive celecoxib or placebo in addition to 
chemotherapy. Of note, this trial was closed after enrollment 
of only 85 of a planned 692 patients due to seven deaths not 
related to disease progression (five in the CapeIRI arm and two 
in the FOLFIRI arm). Analysis of this markedly limited data 
demonstrated worse outcomes with CapeIRI than   FOLFIRI 
and worse outcomes with celecoxib than placebo. The results 
of these trials, and considerable overlap noted between the 
toxicity profiles of capecitabine and irinotecan, have led to 
concern about the use of these two drugs in combination.
Increasing evidence suggests that capecitabine is nonin-
ferior as monotherapy and in combination with oxaliplatin 
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Table 3 Published phase iii trials involving capecitabine in mCRC
Author Regimen Line of  
treatment
No. of  
patients
ORR (%) Median  
PFS (m)
Median  
OS (m)
G 3/4 toxicities
Comparisons of single agent capecitabine to 5-FU/Lv (Mayo)
  Hoff et al44 Capecitabine i 302 24.8* 4.3 12.5 15.4% diarrhea,  
18% HFS, 3% S
5-FU 303 15.5 4.7 13.3 13.9% diarrhea,  
1% HFS, 16% S
  van Cutsem et al45 Capecitabine i 301 18.9 5.2 13.2 10.7% diarrhea,  
16% HFS, 1% S
5-FU 301 15 4.7 12.1 10.4% diarrhea,  
,1% HFS, 13% S
Comparisons of oxaliplatin containing regimens
    Díaz-Rubio et al48 XeLOX i 174 37 8.9 18.1 14% diarrhea,  
2% HFS, 2% S
FUOX 174 46 9.5 20.8 24% diarrhea,  
1% HFS, 4% S
  Porschen et al47 CAPOX i 242 48 7.1 16.8 10% HFS
FUFOX 234 54 8.0 18.8 4% HFS
    Cassidy et al46  
(NO16966)
XeLOX i 1017 37 8.0 19.8 11% diarrhea,  
6% HFS, 1% S
FOLFOX4 1017 37 8.5 19.6 20% diarrhea,  
1% HFS, 2% S
    Hochster et al19  
(TRee-1)
CapeOX i 50 27 5.9 17.2 Refer to Table 1
mFOLFOX6 50 41 8.7 19.2
bFOL 50 20 6.9 17.9
    Rothenberg et al50 XeLOX ii 313 20 4.7 11.9 5% diarrhea,  
HFS 4%, S , 1%
FOLFOX4 314 18 4.8 12.5 19% diarrhea,  
HFS , 1%, S , 1%
Comparison of irinotecan containing regimens
    Fuchs et al52  
(BiCC-C)
CapeiRi i 145 39 5.8 18.9 48% diarrhea,  
32% neutropenia
FOLFiRi 144 47 7.6* 23.1 14% diarrhea,  
43% neutropenia
miFL 141 43 5.9 17.6 19% diarrhea,  
41% neutropenia
    Koopman et al51  
(CAiRO)
Cap/iRi/CAPOX i–iii 410 20 5.8 16.3 23% diarrhea,  
13% HFS 3% S
CAPiRi/CAPOX 410 41* 7.8* 17.4 27% diarrhea,  
7% HFS, 2% S 
    Köhne et al53  
(eORTC 40015)
CapeiRi i 44 34 5.9 14.8 37% diarrhea, 14%  
neutropenia, 9% Cv
FOLFiRi 41 39 9.6* 19.9* 13% diarrhea,  
15% neutropenia
Notes: *Achieved statistical significance. Capecitabine combinations: CapeIRI: capecitabine 1000 mg/m2 twice daily (bid) on days 1–14 + irinotecan 250 mg/m2 q3wk; 
CapeOX: capecitabine 1000 mg/m2 bid on days 1–15 and oxaliplatin 130 mg/m2 on D1 q3wk; XeLOX: capecitabine 1000 mg/m2 bid on days 1–14 and oxaliplatin 130 mg/m2 
on D1 q3wk. 5-FU combinations: bFOL: oxaliplatin 85 mg/m2 on D1 and D15 + 5-FU 500 mg/m2 + Lv 20 mg/m2 on D1, D8, D15 q4wk; FOLFiRi: irinotecan 180 mg/m2, Lv 
400 mg/m2, 5-FU 400 mg/m2 bolus then 5-FU 2400 mg/m2 over 46 h q2wk; FUFOX: oxaliplatin 50 mg/m2, Lv 500 mg/m2, and 5-FU 2000 mg/m2 over 22 h on D1, D8, D15, 
D22 q36 days; FUOX: continuous infusion 5-FU 2250 mg/m2 over 48 h on D1, D8, D15, D22, D29, D36 + oxaliplatin 85 mg/m2 on D1, D15, D29; FOLFOX4: oxaliplatin 
85 mg/m2, Lv 200 mg/m2, 5-FU 400 mg/m2 bolus then 5-FU 600 mg/m2 over 22 h on D1, D2 q2wk; mFOLFOX6: oxaliplatin 85 mg/m2 + Lv 350 mg/m2, 5-FU 400 mg/m2 bolus 
then 5-FU 2400 mg/m2 46-h infusion q2wk.
Abbreviations: HFS, hand–foot syndrome; S, stomatitis; MCRC, metastatic colorectal cancer; ORR, overall response rate; OS, overall survival; PFS, progression-free 
survival; Lv, leucovorin.
settings. The same cannot be said definitively for its use 
with irinotecan due to worse outcomes and toxicity. The 
combination of capecitabine and irinotecan should be used 
with caution, and dose reductions should be considered with 
early signs of toxicity.
Adverse events, elderly patients,  
and other considerations
The side effect profile of capecitabine varies from that of 
5-FU. In a review of 750 patients treated for colorectal 
or breast cancer, .25% of patients experienced anemia, Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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  diarrhea, HFS, nausea, hyperbilirubinemia, fatigue/  weakness, 
abdominal pain, vomiting, and dermatitis.54 Among the 596 
CRC patients in the study, the most common grade 3 toxici-
ties included hyperbilirubinemia (18%), HFS (17%), diarrhea 
(13%), abdominal pain (9%), nausea (4%), vomiting (4%), 
ileus (4%), and fatigue/weakness (4%). Grade 4 toxicities 
occurring in more than 1% of patients included hyperbili-
rubinemia (5%), neutropenia (2%), and diarrhea (2%). As 
discussed earlier, dosing schedules can play a significant role 
in the rate of complications.
In CRC patients, it is particularly important to compare 
the safety profile of capecitabine with 5-FU. In an analysis 
of phase III trials by Walko and Lindley in 2005, the most 
  common toxicities for both capecitabine and 5-FU were fatigue 
(21.1% and 25%) and vomiting (23.3% and 27%).54 Capecit-
abine resulted in a higher rate of HFS (53.3% vs 6.2%), while 
5-FU increased the rate of stomatitis (24.3% vs 61.6%), alope-
cia (6.0% vs 20.6%), neutropenia (1.2% vs 10.3%), diarrhea 
(47.7% vs 58.2%), and nausea (37.9% vs 47.6%). In a recent 
meta-analysis of mCRC trials by Ling et al, similar findings 
were seen when comparing the toxicity profiles of capecitabine 
and 5-FU as outlined in Table 4.43 It is, therefore, important to 
discuss the different side effects with patients, explaining that 
the overall profiles appear to favor capecitabine.
Treatment of elderly patients with capecitabine has been 
a particular focus of recent research due to concerns about 
their ability to tolerate treatment. An abstract presented at 
ASCO in 2004 compared the rate of adverse events among 
patients who were aged between 41 and 60 years with patients 
aged above 70 years.55 The analysis found that the overall 
safety profiles favored capecitabine over 5-FU, with similar 
toxicities across age groups taking capecitabine. A trial of 
51 patients aged above 70 years found similar results with 
67% achieving disease control and only 12% of patients 
exhibiting grade 3 or 4 toxicity on capecitabine.56
The FOCUS2 trial results were published in April 2010, 
specifically looking at the treatment of elderly patients 
with capecitabine and bevacizumab as a first-line regimen 
for mCRC.57 A total of 59 European patients aged above 
70 years were enrolled. Results showed a 34% response rate 
with 71% of patients achieving disease control at a dose of 
1250 mg/m2 twice daily. A total of 54% of patients had grade 
3 or 4 toxicities and four patients died due to treatment-related 
complications. A higher rate of grade 3 and 4 toxicities was 
seen in patients with decreased renal clearance. A trial in Italy 
compared CAPOX with CAPIRI among 94 patients aged 
above 70 years.58 Similar outcomes were seen in both groups; 
however, CAPOX was better tolerated with less grade 3 or 4 
diarrhea (32% vs 15%), less neutropenia (23% vs 6%), and 
an improved global health status (45% vs 21%).
These trials indicate that capecitabine can be administered 
to patients aged above 70 as long as they desire aggressive 
care and are comfortable with the rate of adverse reactions 
outlined. Capecitabine should be avoided in elderly patients 
with renal dysfunction or overlapping toxicities.
Another concern has been the increased toxicity seen 
in patients treated with capecitabine after prior exposure to 
5-FU.59 A trial randomizing patients to sequential treatment 
with weekly bolus 5-FU followed by capecitabine or capecit-
abine followed by 5-FU was closed after accruing 40 of the 
planned 74 patients because of excessive sequence-specific 
toxicity. The mechanism behind this finding is unclear, and 
it is not clear if this would still be seen with a longer delay 
between exposures to these agents. Of note, this data is very 
limited and does not necessarily apply to modern infusional 
5-FU regimens.
Pharmacoeconomics
Reimbursement policies vary internationally and even region-
ally within the United States. Multiple analyses have shown cost 
savings when capecitabine is compared to 5-FU, but variability 
in insurance coverage for oral cytotoxics can lead to signifi-
cantly higher out-of-pocket expenses for patients, especially 
since 5-FU is usually fully covered by insurance plans.
In a 2009 article by Chu et al, patients treated with 
capecitabine for CRC were assessed for the frequency and 
expense of a range of common complications.60 Among 4973 
patients, the mean predicted monthly complication cost was 
136% greater with 5-FU monotherapy when compared to 
capecitabine. This equated to an additional US$601/month 
(95% CI: $469–$737) spent treating complications associated 
with 5-FU. When each agent was given in combination with 
oxaliplatin, this value increased to US$1165/month (95% 
CI: $892–$1595). The costs of administering the drugs were 
not included in the calculation as both values were similar.
Table 4 Comparison of grade 3 and 4 events in patients treated with 
capecitabine in trials as opposed 5-FU per a recent   meta-analysis of 
mCRC trials43
G 3/4 AE No. of trials No. of patients OR 95% CI
Thrombocytopenia 6 2612 1.45 0.82–2.55
Diarrhea* 10 4720 1.35 1.16–1.57
Nausea/vomiting 8 4668 1.06 0.84–1.33
Neuropathy 7 4525 1.04 0.82–1.32
Neutropenia* 9 4786 0.15 0.12–0.18
Note: *Statistically significant.
Abbreviations: 5-FU, 5-fluorouracil; mCRC, metastatic colorectal cancer; AE, adverse 
events; OR, odds ratio; CI, confidence interval.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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An analysis of the X-ACT trial (which evaluated 
capecitabine versus 5-FU in the adjuvant treatment of CRC) 
showed the cost of treating patients with capecitabine in 
the United Kingdom was 57% lower than that for 5-FU.61 
Capecitabine use led to decreased hospitalization rates and 
cost savings of £3653. Societal costs for such things as patient 
travel and time off work were also lowered by £1318, again 
reinforcing the potential cost benefit of capecitabine.
An analysis comparing costs between XELOX and 
  FOLFOX4 as a part of trials NO16966 and NO16967 was 
also reported in 2009.62 In the analysis, the authors found the 
incremental improvement in quality-adjusted progression free 
survival days (QAPFSD) favored XELOX over FOLFOX4 in 
both first- and second-line settings. Specifically, patients gained 
10.5 QAPFSD from first-line and 11.3 QAPFSD from second-
line treatment. Cost calculations found savings for the National 
Health Service of £7600 and £3900 for patients treated with 
XELOX in first- and second-line settings, respectively.
Finally, a study published in the United States demonstrated 
a lower cost with capecitabine monotherapy when compared to 
5-FU and leucovorin of US$6683 versus US$9304.63 It showed 
a higher acquisition cost for capecitabine but lower administra-
tion and complication costs. This held true when oxaliplatin was 
added to the regimens with costs of US$11,463 and US$14,320. 
Overall, these studies demonstrate a measurable cost saving 
when using capecitabine in place of 5-FU. However, most of 
these studies are limited in that the overall costs to the patient, 
provider, and payer are not considered in the calculation.
Conclusion
In the past decade, capecitabine has been heavily investi-
gated in all CRC treatment settings. Although it was initially 
approved for use by the FDA in the adjuvant setting for 
stage III disease, the most robust data exist in the metastatic 
setting. Its off-label use is quickly growing and will continue 
to do so, pending the publication of a number of ongoing 
clinical trials, especially in the adjuvant and neoadjuvant 
settings. For metastatic disease, the evidence is fairly robust, 
showing capecitabine to be noninferior to 5-FU as mono-
therapy or as a part of a combined regimen with oxaliplatin. 
The same cannot be said for combinations with irinotecan 
as overlapping toxicity profiles lead to poor tolerability, and 
studies have had trouble demonstrating equivalent outcomes. 
In the adjuvant setting, the X-ACT trial established borderline 
superiority to treatment with capecitabine, while a Japanese 
meta-analysis showed noninferiority when compared to 
observation alone. This is encouraging for capecitabine 
use. Studies with capecitabine in the neoadjuvant setting 
have at least demonstrated efficacy and tolerability, but two 
major ongoing studies will hopefully shed more light on 
capecitabine in direct comparison to 5-FU with radiation in 
the neoadjuvant treatment of rectal cancer.
In addition to disease outcomes such as PFS and OS, 
patients should be informed about differences in the side effect 
profiles between capecitabine and 5-FU and   out-of-pocket 
costs. Depending on insurance coverage, capecitabine use 
in place of 5-FU may be less expensive for the system as a 
whole but may result in significantly higher out-of-pocket 
costs for a particular individual. Extra care must also be taken 
with the treatment of elderly patients and in making dosing 
decisions in the United States versus abroad.
Overall, capecitabine presents a promising step forward 
in transitioning treatment from infusional therapy to oral 
therapy, thereby limiting the time a patient with cancer must 
spend in clinic. More robust quality of life data would help to 
reinforce this claim. However, care must be taken to ensure 
that there is adequate information to truly support off-label 
use of expensive oncologic drugs; ongoing trials will be 
critical in supporting clinical decisions.
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